KLK3 and prostate cancer: In addition, there was little evidence to support an effect of SGLT2 inhibition on prostate-specific antigen (PSA) levels (β = −0.14, 95% CI = −0.30 to 0.03, p = 0.11; Table S6), which suggested that SGLT2 inhibition is likely to show an effect on reducing risk rather than influencing the diagnostic workup for prostate cancer.